Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase
This is a study of a melanoma tumor antigen peptide vaccine. Peptides representing HLA-A201
restricted T cell epitopes of the melanoma antigens, MART-1, gp100 and tyrosinase will be
administered emulsified in Incomplete Freund's Adjuvant, (IFA) to HLA-A201 patients with
melanoma. The study is designed to evaluate the potential therapeutic role, immunologic
effects and toxicity of repeated doses of this peptide vaccine administered subcutaneously.
Immune reactivity to the peptide epitope will be monitored in all patients by analysis of
melanoma-specific T cell precursors prior to and after immunization.
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
United States: Federal Government
|National Cancer Institute (NCI)||Bethesda, Maryland 20892|